Cardiovascular profile of the new diabetes medication, ozempic


A nice video summary by NEJM regarding cardiovascular safety of semaglutide. Semaglutide was approved by the FDA in December 2017. It is a weekly GLP-1 agonist with hyperglycemic and weight loss benefits while safe from cardiac standpoint.


Also see:

FDA approval of ozempic

Other semaglutide/ozempic related posts

GLP-1 agonist related posts